Clinical features of CIDP with LM1-associated antibodies
Clinical features of CIDP with LM1-associated antibodies
复制标题
DOI：
10.1136/jnnp-2012-303440
复制
发表时间：
2013-05-01
影响因子：
11
通讯作者：
Kusunoki, Susumu
中科院分区：
文献类型：
--
作者：
Kuwahara, Motoi;Suzuki, Hidekazu;Kusunoki, Susumu
背景LM 1是人外周神经髓鞘中主要的糖脂，在一些慢性炎性脱髓鞘性多发性神经病（CIDP）患者中检测到针对LM 1和含LM 1的神经节苷脂复合物的抗体。方法检测75例CIDP患者血清中LM 1抗体、GM 1/LM 1抗体、GD 1b/LM 1抗体。结果75例CIDP患者中，2例抗LM 1抗体阳性，3例抗GM 1/LM 1复合物抗体阳性，1例抗GD 1b/LM 1复合物抗体阳性，2例同时抗GM 1/LM 1和GD 1b/LM 1复合物抗体阳性。携带LM 1相关抗体的患者没有颅神经缺损（p
Background LM1 is the predominant glycolipid in human peripheral nerve myelin and antibodies to LM1 and LM1-containing ganglioside complexes are detected in some patients with chronic inflammatory demyelinating polyneuropathy (CIDP). The clinical features of patients with such antibodies have not yet been investigated.Methods Serum antibodies to LM1, a mixture of GM1 and LM1 (GM1/LM1), and that of GD1b and LM1 (GD1b/LM1) were examined in 75 consecutive patients with CIDP. The clinical features of the CIDP patients with such antibodies in the present series and those in the previous reports were investigated and compared with those of antibody-negative patients.Results Of the 75 patients with CIDP, two had antibodies to LM1, three had anti-GM1/LM1 complex antibody, one had anti-GD1b/LM1 complex antibody and two had antibodies to both the GM1/LM1 and GD1b/LM1 complexes. Patients with the LM1-associated antibodies did not have cranial nerve deficits (p